Researchers from Fundacio Privada Instituto de Salud Global Barcelona (ISGLOBAL), Institut de Bioenginyeria de Catalunya (IBEC) and Universitat de Barcelona have described compounds reported to be useful for the treatment of malaria.
Scientists from the University of Delhi and affiliated organizations have reported the discovery and preclinical characterization of novel compounds with antiplasmodial activity.
Working from a lead tetrahydro-beta-carboline acid product which had been found to have antimalarial properties and to act as an inhibitor of MEP, Virginia Tech and University of Georgia scientists and their collaborators synthesized related compounds.
An international collaborative study has identified several novel derivatives of anticancer proteasome inhibitors (PIs) that had potential as antimalarials, the authors reported in the September 28, 2021, online edition of Proceedings of the National Academy of Sciences.
A collaboration aimed at identifying and developing potential new antimalarial drug candidate drugs has been announced between Walter and Eliza Hall Institute for Medical Research in Melbourne, Australia, and Janssen Pharmaceutica, with assistance from Johnson & Johnson Innovation. The collaboration has already discovered promising compounds with antimalarial activity from among 80,000 drug-like molecules in the Janssen Jumpstarter Compound Library, a collection of drug-like compounds designed to fast-track discovery of new medicines.
